Medical Policy
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias

Table of Contents
- Policy: Commercial
- Coding Information
- Policy: Medicare
- Description
- Authorization Information
- Policy History
- Information Pertaining to All Policies
- References

Policy Number: 190
BCBSA Reference Number: 8.01.22
NCD/LCD: National Coverage Determination (NCD) for Stem Cell Transplantation Formerly 110.8.1 (110.23)

Related Policies
- Hematopoietic Cell Transplantation for Autoimmune Diseases, #192

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity
Medicare HMO BlueSM and Medicare PPO BlueSM Members

Allogeneic hematopoietic stem cell transplantation (HCT) is considered MEDICALLY NECESSARY for select patients with the following disorders:

Hemoglobinopathies
- Sickle cell anemia for children or young adults with either a history of prior stroke or at increased risk of stroke or end-organ damage
- Homozygous beta-thalassemia (i.e., thalassemia major).

Bone Marrow Failure Syndromes
- Aplastic anemia including hereditary (including Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond, Diamond-Blackfan) or acquired (e.g., secondary to drug or toxin exposure) forms.

Primary Immunodeficiencies*
- Absent or defective T-cell function (e.g., severe combined immunodeficiency, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome)
- Absent or defective natural killer function (e.g. Chediak-Higashi syndrome)
- Absent or defective neutrophil function (e.g. Kostmann syndrome, chronic granulomatous disease, leukocyte adhesion defect).
*The following lists the immunodeficiencies that have been successfully treated by allogeneic hematopoietic stem cell transplantation (allo-HCT) (Gennery & Cant et al, 2008).

**Lymphocyte Immunodeficiencies**
- Adenosine deaminase deficiency
- Artemis deficiency
- Calcium channel deficiency
- CD 40 ligand deficiency
- Cernunnos/X-linked lymphoproliferative disease deficiency
- CHARGE syndrome with immune deficiency
- Common gamma chain deficiency
- Deficiencies in CD45, CD3, CD8
- DiGeorge syndrome
- DNA ligase IV deficiency syndrome
- Interleukin-7 receptor alpha deficiency
- Janus-associated kinase 3 (JAK3) deficiency
- Major histocompatibility class II deficiency
- Omenn syndrome
- Purine nucleoside phosphorylase deficiency
- Recombinase-activating gene (RAG) 1/2 deficiency
- Reticular dysgenesis
- Winged helix deficiency
- Wiskott-Aldrich syndrome
- X-linked lymphoproliferative disease
- Zeta-chain-associated protein-70 (ZAP-70) deficiency

**Phagocytic Deficiencies**
- Chédiak-Higashi syndrome
- Chronic granulomatous disease
- Griscelli syndrome type 2
- Hemophagocytic lymphohistiocytosis
- Interferon-gamma receptor deficiencies
- Leukocyte adhesion deficiency
- Severe congenital neutropenias
- Shwachman-Diamond syndrome

**Other Immunodeficiencies**
- Autoimmune lymphoproliferative syndrome
- Cartilage hair hypoplasia
- CD25 deficiency
- Hyper IgD and IgE syndromes
- ICF syndrome
- IPEX syndrome
- NEMO deficiency
- NF-κB inhibitor, alpha (IκB-alpha) deficiency
- Nijmegen breakage syndrome

**Inherited Metabolic Diseases**
- Lysosomal and peroxisomal storage disorders except Hunter, Sanfilippo, and Morquio syndromes

**In the inherited metabolic disorders, allo-HCT has been proven effective in some cases of Hurler, Maroteaux-Lamy, and Sly syndromes, childhood onset cerebral X-linked adrenoleukodystrophy, globoid cell leukodystrophy, metachromatic leukodystrophy, alpha-mannosidosis, and aspartylglucosaminuria. Allogeneic HCT is possibly effective for fucosidosis, Gaucher types 1 and 3, Farber lipogranulomatosis,
galactosialidosis, GM1 gangliosidosis, mucolipidosis II (I-cell disease), multiple sulfatase deficiency, Niemann-Pick, neuronal ceroid lipofuscinosis, sialidosis, and Wolman disease. Allogeneic HSCT has not been effective in Hunter, Sanfilippo, or Morquio syndromes (Mehta, 2004).

**Genetic Disorders Affecting Skeletal Tissue**
- Infantile malignant osteopetrosis (Albers-Schonberg disease or marble bone disease).

**Medicare HMO BlueSM and Medicare PPO BlueSM Members**

Medical necessity criteria and coding guidance can be found through the link below.

[National Coverage Determination (NCD) for Stem Cell Transplantation Formerly 110.8.1 (110.23)]

**Prior Authorization Information**
Pre-service approval is required for all inpatient services for all products.
See below for situations where prior authorization may be required or may not be required for outpatient services.
Yes indicates that prior authorization is required.
No indicates that prior authorization is not required.
N/A indicates that this service is primarily performed in an inpatient setting.

<table>
<thead>
<tr>
<th>Service Type</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>N/A</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>N/A</td>
</tr>
<tr>
<td>Medicare HMO BlueSM</td>
<td>N/A</td>
</tr>
<tr>
<td>Medicare PPO BlueSM</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**CPT Codes / HCPCS Codes / ICD Codes**

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

**CPT Codes**

<table>
<thead>
<tr>
<th>CPT codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>38205</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic</td>
</tr>
<tr>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>38240</td>
<td>Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic</td>
</tr>
</tbody>
</table>

**HCPCS Codes**

<table>
<thead>
<tr>
<th>HCPCS codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2140</td>
<td>Cord blood harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>S2142</td>
<td>Cord blood derived stem-cell transplantation, allogeneic</td>
</tr>
</tbody>
</table>
Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)

### ICD-10 Procedure Codes

<table>
<thead>
<tr>
<th>ICD-10-PCS procedure codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>30233G1 Transfusion of Nonautologous Bone Marrow into Peripheral Vein, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>30233X1 Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>30233Y1 Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>30243G1 Transfusion of Nonautologous Bone Marrow into Central Vein, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>30243X1 Transfusion of Nonautologous Cord Blood Stem Cells into Central Vein, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>30243Y1 Transfusion of Nonautologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>30263G1 Transfusion of Nonautologous Bone Marrow into Central Artery, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>30263X1 Transfusion of Nonautologous Cord Blood Stem Cells into Central Artery, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>30263Y1 Transfusion of Nonautologous Hematopoietic Stem Cells into Central Artery, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>3E03305 Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>3E04305 Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>3E05305 Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach</td>
<td></td>
</tr>
<tr>
<td>3E06305 Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach</td>
<td></td>
</tr>
</tbody>
</table>

**Description**

**HEMATOPOIETIC CELL TRANSPLANTATION**

Hematopoietic cell transplantation (HCT) refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in patients who receive bone marrow toxic doses of cytotoxic drugs with or without whole-body radiotherapy. Allogeneic HCT (allo-HCT) refers to the use of hematopoietic progenitor cells obtained from a donor. They can be harvested from bone marrow, peripheral blood, or umbilical cord blood and placenta shortly after delivery of neonates. Cord blood is discussed in greater detail in [policy #285](#).

Immunologic compatibility between infused hematopoietic cells and the recipient is a critical factor for achieving a good outcome with allo-HCT. Compatibility is established by typing of human leukocyte antigen (HLA) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci (except umbilical cord blood).

**Preparative Conditioning for Allo-HCT**

The conventional practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. Reduced-intensity conditioning refers to chemotherapy regimens that seek to reduce adverse effects secondary to bone marrow toxicity. These regimens partially eradicate the patient’s hematopoietic ability, thereby allowing for relatively prompt hematopoietic recovery. Patients
who undergo reduced-intensity conditioning with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism. A number of different cytotoxic regimens, with or without radiotherapy, may be used for reduced-intensity conditioning allogeneic transplantation. They represent a continuum in their intensity, from almost totally myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition.

GENETIC DISEASES AND ACQUIRED ANEMIAS

Hemoglobinopathies

The thalassemias result from mutations in the globin genes, resulting in reduced or absent hemoglobin production, thereby reducing oxygen delivery. The supportive treatment of Beta-thalassemia major requires life-long red blood cell transfusions that lead to progressive iron overload and the potential for organ damage and impaired cardiac, hepatic, and endocrine function. The only definitive cure for thalassemia is to correct the genetic defect with allo-HCT.

Sickle cell disease is caused by a single amino acid substitution in the beta chain of hemoglobin and, unlike thalassemia major, has a variable course of clinical severity. Sickle cell disease typically manifests clinically with anemia, severe painful crises, acute chest syndrome, stroke, chronic pulmonary and renal dysfunction, growth retardation, neurologic deficits, and premature death. The mean age of death for patients with sickle cell disease has been demonstrated as 42 years for men and 48 for women. Three major therapeutic options are available: chronic blood transfusions, hydroxyurea, and allo-HCT, the latter being the only possibility for cure.

Bone Marrow Failure Syndromes

Aplastic anemia in children is rare and is most often idiopathic and less commonly, due to a hereditary disorder. Inherited syndromes include Fanconi anemia, a rare, autosomal recessive disease characterized by genomic instability, with congenital abnormalities, chromosome breakage, cancer susceptibility, and progressive bone marrow failure leading to pancytopenia and severe aplastic anemia. Frequently, this disease terminates in a myelodysplastic syndrome or acute myeloid leukemia. Most patients with Fanconi anemia succumb to the complications of severe aplastic anemia, leukemia, or solid tumors, with a median survival of 30 years of age. In Fanconi anemia, HCT is currently the only treatment that definitively restores normal hematopoiesis. Excellent results have been observed with the use of HLA-matched sibling allo-HCT, with cure of the marrow failure and amelioration of the risk of leukemia.

Dyskeratosis congenita is characterized by marked telomere dysregulation with clinical features of reticulated skin hyperpigmentation, nail dystrophy, and oral leukoplakia. Early mortality is associated with bone marrow failure, infections, pulmonary complications, or malignancy.

Variants affecting ribosome assembly and function are associated with Shwachman-Diamond syndrome and Diamond-Blackfan syndrome. Shwachman-Diamond has clinical features that include pancreatic exocrine insufficiency, skeletal abnormalities, and cytopenias, with some patients developing aplastic anemia. As with other bone marrow failure syndromes, patients are at increased risk of myelodysplastic syndrome and malignant transformation, especially acute myeloid leukemia. Diamond-Blackfan anemia is characterized by absent or decreased erythroid precursors in the bone marrow, with 30% of patients also having a variety of physical anomalies.

Primary Immunodeficiencies

The primary immunodeficiencies are a genetically heterogeneous group of diseases that affect distinct components of the immune system. More than 120 gene defects have been described, causing more than 150 disease phenotypes. The most severe defects (collectively known as severe combined immunodeficiency) cause an absence or dysfunction of T lymphocytes and sometimes B lymphocytes and natural killer cells. Without treatment, patients with severe combined immunodeficiency usually die by 12 to 18 months of age. With supportive care, including prophylactic medication, the lifespan of these patients can be prolonged, but long-term outlook is still poor, with many dying from infectious or inflammatory complications or malignancy by early adulthood. Bone marrow transplantation is the only
definitive cure, and the treatment of choice for severe combined immunodeficiency and other primary immunodeficiencies, including Wiskott-Aldrich syndrome and congenital defects of neutrophil function.\(^5\)

**Inherited Metabolic Diseases**

Lysosomal storage disorders consist of many different rare diseases caused by a single gene defect, and most are inherited as an autosomal recessive trait.\(^6\) Lysosomal storage disorders are caused by specific enzyme deficiencies that result in defective lysosomal acid hydrolysis of endogenous macromolecules that subsequently accumulate as a toxic substance. Peroxisomal storage disorders arise due to a defect in a membrane transporter protein that leads to defects in the metabolism of long-chain fatty acids. Lysosomal storage disorders and peroxisomal storage disorders affect multiple organ systems, including the central and peripheral nervous systems. These disorders are progressive and often fatal in childhood due to both the accumulation of toxic substrate and a deficiency of the product of the enzyme reaction.\(^6\) Hurler syndrome usually leads to premature death by 5 years of age.

Exogenous enzyme replacement therapy is available for a limited number of the inherited metabolic diseases; however, these drugs do not cross the blood-brain barrier, which results in the ineffective treatment of the central nervous system. Stem cell transplantation provides a constant source of enzyme replacement from the engrafted donor cells, which are not impeded by the blood-brain barrier.\(^6\) The donor-derived cells can migrate and engraft in many organ systems, giving rise to different types of cells (eg, microglial cells in the brain and Kupffer cells in the liver).\(^6\)

Allogeneic HCT has been primarily used to treat the inherited metabolic diseases that belong to the lysosomal and peroxisomal storage disorders, as listed in Table 1.\(^6\) The first stem cell transplant for an inherited metabolic disease was performed in 1980 in a patient with Hurler syndrome. Since that time, more than 1000 transplants have been performed worldwide.\(^6\)

**Table 1. Lysosomal and Peroxisomal Storage Disorders**

<table>
<thead>
<tr>
<th>Category</th>
<th>Diagnosis</th>
<th>Other Names</th>
</tr>
</thead>
</table>
| Mucopolysaccharidosis | Mucopolysaccharidosis I H or H/S  
Mucopolysaccharidosis II  
Mucopolysaccharidosis III A-D  
Mucopolysaccharidosis IV A-B  
Mucopolysaccharidosis VI  
Mucopolysaccharidosis VII | Hurler syndrome or Hurler-Scheie syndrome  
Hunter syndrome  
Sanfilippo syndrome A-D Morquio syndrome A-B Maroteaux-Lamy syndrome  
Sly syndrome |
| Sphingolipidosis | Fabry disease  
Farber disease Gaucher disease types 1 and 3  
GM\(_1\) gangliosidosis  
Niemann-Pick disease A and B  
Tay-Sachs disease  
Sandhoff disease  
Globoid cell leukodystrophy  
Metachromatic leukodystrophy | Lipogranulomatosis  
Krabbe disease  
MLD |
| Glycoproteinosis | Aspartylglucosaminuria Fucosidosis  
Alpha-mannosidosis Beta-mannosidosis  
Mucolipidosis III and IV | Sialidosis |
| Other lipidoses | Niemann-Pick disease C Wolman disease  
Ceroid lipofuscinosis type III | Batten disease |
<p>| Glycogen storage | Glycogen storage disease type II | Pompe disease |</p>
<table>
<thead>
<tr>
<th>Multiple enzyme deficiency</th>
<th>Galactosialidosis Mucolipidosis type II</th>
<th>I-cell disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysosomal transport defects</td>
<td>Cystinosis Sialic acid storage disease</td>
<td>Salla disease</td>
</tr>
<tr>
<td>Peroxisomal storage disorders</td>
<td>Adrenoleukodystrophy</td>
<td>ALD AMN</td>
</tr>
</tbody>
</table>

**Genetic Disorders Affecting Skeletal Tissue**

Osteopetrosis is a condition caused by defects in osteoclast development and/or function. The osteoclast (the cell that functions in the breakdown and resorption of bone tissue) is known to be part of the hematopoietic family and shares a common progenitor with the macrophage in the bone marrow.\(^7\) Osteopetrosis is a heterogeneous group of heritable disorders, resulting in several different types of variable severity. The most severely affected patients are those with infantile malignant osteopetrosis (Albers-Schonberg disease or marble bone disease). Patients with infantile malignant osteopetrosis suffer from dense bone, including a heavy head with frontal bossing, exophthalmos, blindness by approximately 6 months of age, and severe hematologic malfunction with bone marrow failure.\(^7\) Seventy percent of these patients die before the age of 6 years, often of recurrent infections.\(^7\) HCT is the only curative therapy for this fatal disease.

HCT for autoimmune disease, such as rheumatoid arthritis or multiple sclerosis, is considered separately in policy #192.

**Summary**

A number of inherited and acquired conditions have the potential for severe and/or progressive disease. For some conditions, allogeneic hematopoietic cell transplantation (allo-HCT) has been used to alter the natural history of the disease or potentially offer a cure.

For individuals who have a hemoglobinopathy, bone marrow failure syndrome, primary immunodeficiency, inherited metabolic syndrome disease, or a genetic disorder affecting skeletal tissue who receive allo-HCT, the evidence includes mostly case series, case reports, and registry data. Relevant outcomes are overall survival, disease-specific survival, symptoms, quality of life, and treatment-related morbidity. The evidence has shown that, for most of these disorders, there is a demonstrable improvement in overall survival and other disease-specific outcomes. The exception has been the use of allo-HCT in the inherited metabolic diseases like Hunter, Sanfilippo, and Morquio syndromes. Allo-HCT is likely to improve health outcomes in select patients with certain inherited and acquired diseases. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/2018</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>12/2017</td>
<td>BCBSA National medical policy review. &quot;Stem&quot; removed from title and Policy. HSCT changed to HCT in policy text. Policy statement unchanged. 12/1/2017</td>
</tr>
<tr>
<td>12/2016</td>
<td>Coverage clarified for Medicare Advantage based on National Coverage Determination (NCD) for Stem Cell Transplantation Formerly 110.8.1 (110.23). 12/14/2016</td>
</tr>
<tr>
<td>9/2015</td>
<td>Clarified coding information.</td>
</tr>
<tr>
<td>6/2014</td>
<td>Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.</td>
</tr>
<tr>
<td>12/2013</td>
<td>New references from BCBSA National medical policy.</td>
</tr>
</tbody>
</table>
Information Pertaining to All Blue Cross Blue Shield Medical Policies
Click on any of the following terms to access the relevant information:
Medical Policy Terms of Use
Managed Care Guidelines
Indemnity/PPO Guidelines
Clinical Exception Process
Medical Technology Assessment Guidelines

References
transplantation is an effective treatment for patients with SLAM deficiency. Marsh RA, Bleesing JJ, Chandrakasan S, et al. Reduced PMID 11238097


